Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 698

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1C
Chunk 698
---
 from August 2012
to August 2021 where he managed diverse global investment funds totaling over two billion U.S dollars. Mr. Kim is proficient
in English. He earned his LL.B from Konkuk University, Korea in 1998 and earned an LL.M from the University of Minnesota, Twin Cities
in 2010.

Gihyoun Bang has been the Chief Financial Officer of the Company
since February 14, 2025. Mr. Bang has also been the Chief Financial Officer of OSR, a position he has held since June 2024. Mr. Bang
is responsible for planning, managing and running overall finance activities of OSR and its subsidiary companies, including producing
the group’s consolidated financial statements for external audits. Previously, Mr. Bang served as chief operating officer for
Newlake Alliance Management Co., Ltd., a private equity firm based in Seoul, South Korea, from February 2019 to June 2024, where
he led private equity investments, managed fund raising and managed the organization. Mr. Bang previously served as team head, equity
capital markets, and other positions for Shinhan Securities Co. Ltd., in South Korea. Mr. Bang is a certified public accountant
in the U.S., a certified credit analyst in Korea and a certified investment manager in Korea. Mr. Bang received his B.A. in Business
Administration from Hansung University in 2002.

Dr. Constance Höfer has been the Chief Scientific Officer
of the Company since March 24, 2025. Dr. Höfer is a seasoned leader in drug development with over 20 years of experience in oncology
and immunology and will oversee OSR Holdings’ scientific strategy and innovation pipeline. Dr. Höfer joins OSR Holdings from
Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held
senior leadership positions at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, playing a key role in advancing therapeutic programs
across various modalities, including New Biological Entities (NBEs), New Chemical Entities (NCEs), nucleotides, and viral and cell-based
therapies. Coupled with her extensive industry experience and a PhD in Pharmacology from the University of Newcastle, Dr. Höfer has
a strong foundation in clinical pharmacology and translational medicine, ensuring a seamless transition from early